

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Cancer Treatments Advisory Committee provisional recommendations 7 August 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Mirvetuximab soravtansine-gynx for treatment of folate receptor alpha high, platinum resistant, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, within the context of treatments for malignancy, subject to Special Authority criteria	Medium priority
Pembrolizumab for first-line treatment of advanced or recurrent dMMR endometrial cancer, in combination with chemotherapy, followed by maintenance monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria	High priority
Pembrolizumab for first-line treatment of advanced or recurrent pMMR endometrial cancer, in combination with chemotherapy, followed by maintenance monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria	Medium priority
Pembrolizumab for second-line treatment of advanced or recurrent dMMR endometrial cancer, as monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria	High priority
Pembrolizumab for second-line treatment of advanced or recurrent pMMR endometrial cancer, in combination with lenvatinib, within the context of treatments for malignancy, subject to Special Authority criteria	High priority
Durvalumab for first-line treatment of advanced, metastatic or recurrent dMMR endometrial cancer, in combination with chemotherapy, followed by maintenance monotherapy, within the context of treatments for malignancy, subject to Special Authority criteria	High priority
Durvalumab for first-line treatment of advanced, metastatic or recurrent, pMMR endometrial cancer, in combination with chemotherapy, followed by maintenance durvalumab in combination with olaparib, within the context of treatments for malignancy, subject to Special Authority criteria	Medium priority
Durvalumab for first-line treatment of advanced, metastatic or recurrent, endometrial cancer (all comers), in combination with chemotherapy, followed by maintenance durvalumab as monotherapy or in combination with olaparib, within the context of treatments for malignancy, subject to Special Authority criteria	Medium priority

[More information about the agenda items considered at the recent Cancer Treatments Advisory Committee meeting can be found on the Pharmac website here.](#)

Released 19 August 2026